AmDerma Pharmaceuticals, LLC
Records under this name other than patents AmDerma Pharmaceuticals, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to AmDerma Pharmaceuticals, LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,511,044 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer Lapsed on the fee record Ended Dec 6, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 6, 2024 | From the USPTO record |
| US 10,632,085 | Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts Lapsed on the fee record Ended Apr 28, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 28, 2024 | From the USPTO record |
| US 9,301,931 | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis Lapsed on the fee record Ended Apr 5, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 5, 2024 | From the USPTO record |
| US 8,101,660 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer Lapsed on the fee record Ended Jan 24, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 24, 2024 | From the USPTO record |
| US 9,227,928 | Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts Lapsed on the fee record Ended Jan 5, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 5, 2024 | From the USPTO record |
| US 9,192,592 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis Formerly held Lapsed on the fee record Ended Nov 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 24, 2023 | From the USPTO record |
| US 10,441,530 | Skin penetration enhancing systems for polar drugs Lapsed on the fee record Ended Oct 15, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 15, 2023 | From the USPTO record |
| US 10,434,076 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis Formerly held Lapsed on the fee record Ended Oct 8, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 8, 2023 | From the USPTO record |
| US 7,968,531 | Use of 2,5-dihydroxybenzenesulphonic acid in the production of medicaments for the treatment of angiodependent diseases such as cancer and psoriasis Lapsed on the fee record Ended Jun 28, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jun 28, 2023 | From the USPTO record |
| US 10,278,940 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer Lapsed on the fee record Ended May 7, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 7, 2023 | From the USPTO record |